Resumen de: US2019276868A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

Resumen de: US2019275128A1

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Resumen de: WO2019173838A1

Disclosed herein are methods and systems for rapid detection of microorganisms using a cell binding component (CBC). The specificity of CBSs for binding microorganisms allows targeted and highly specific detection of a microorganism of interest.

Resumen de: WO2018096007A2

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

Resumen de: CN110205277A

本发明公开了一种肠炎沙门菌glpK基因缺失的应用，利用λ‑Red重组技术构建肠炎沙门菌glpK基因缺失株，并对其生物学特性和毒力进行研究，明确了glpK基因缺失引起肠炎沙门菌毒力下降，为设计肠炎沙门菌疫苗靶点提供参考，进而防治肠炎沙门菌感染。

Resumen de: WO2018081502A1

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

Resumen de: NZ742089A

The invention relates to bird feed comprising synthetic capsaicinoids for prohylactic use of the general formula for treatment of salmonella infection.

Resumen de: WO2019164194A1

The present invention relates to: a Podoviridae bacteriophage Sal-HEP-1 (accession number: KCTC 13454BP) isolated from nature, the Podoviridae bacteriophage Sal-HEP-1 having the ability to kill Salmonella Heidelberg bacteria and having a genome represented by SEQ ID NO: 1; and a method for preventing and treating diseases induced by the Salmonella Heidelberg bacteria by using a composition containing the Podoviridae bacteriophage Sal-HEP-1 as an active ingredient.

Resumen de: WO2019164194A1

The present invention relates to: a Podoviridae bacteriophage Sal-HEP-1 (accession number: KCTC 13454BP) isolated from nature, the Podoviridae bacteriophage Sal-HEP-1 having the ability to kill Salmonella Heidelberg bacteria and having a genome represented by SEQ ID NO: 1; and a method for preventing and treating diseases induced by the Salmonella Heidelberg bacteria by using a composition containing the Podoviridae bacteriophage Sal-HEP-1 as an active ingredient.

Resumen de: US2018187181A1

Disclosed are methods for lysis of cells, such as bacteria present in microbiomes, that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allows for simplified removal of detergent after lysis, and importantly, yields improved quantities of genomic DNA (gDNA) from difficult to lyse bacteria.

Resumen de: SG11201903333SA

ScreeningRisk Assessment Low Risk High Risk Quality Measures Reported 0 Shelf-life & Freshness (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 July 2019 (04.07.2019) WIPO I PCT 11111111111111011111111111111110111110101111111111111111111111111111111111111011110111111 (10) International Publication Number WO 2019/133756 Al (51) International Patent Classification: BO1J 19/00 (2006.01) Cl 2N 15/09 (2006.01) C12N 9/00 (2006.01) Cl 2P 19/34 (2006.01) C12N 9/10 (2006.01) Cl 2Q 1/68 (2018.01) C12N 9/16 (2006.01) (21) International Application Number: PCT/US2018/067750 (22) International Filing Date: 27 December 2018 (27.12.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/611,846 29 December 2017 (29.12.2017) US 62/646,135 21 March 2018 (21.03.2018) US 62/730,288 12 September 2018 (12.09.2018) US (71) Applicant: CLEAR LABS, INC. [US/US]; 3565 Haven Avenue, Suite 2, Menlo Park, California 94025 (US). (72) Inventors: AMINI, Sasan; 626 Poplar Avenue, Redwood City, California 94061 (US). KHAKSAR, Ramin; 131 Santa Clara Avenue, Redwood City, California 94061 (US). TAYLOR, Michael; 10805 Torrance Drive, Kens- ington, Maryland 20895 (US). SHOKRALLA, Shadi; 716 Westbrook Ct., Danville, California 94506 (US). HANEY, Christopher; 100 N Whisman Rd., #1313, Mountain View, California 94043 (US). VAIDYANATHAN, Pava

Resumen de: CN110172087A

本发明提供了一种O抗原亲和介质及其制备方法和应用，所述O抗原亲和介质包括超大孔介质和沙门氏菌的O抗原，所述O抗原化学固定在超大孔介质表面。本发明的O抗原亲和基质制备过程简单，纯化操作简便，效率高，利用该亲和介质和纯化方法制备出的抗体对O抗原具有高特异性，可用于辅助沙门氏菌诊断等应用。

Resumen de: US2019257832A1

The present invention relates to means and method for isolating naturally-occurring microorganisms (non-pathogenic bacteria, yeasts or fungi) capable of binding toxins from microorganisms such as bacteria, viruses, fungi, yeasts, or protozoans and/or receptors for these toxins on the surface of mammalian cells, thereby making these receptors inaccessible for said toxins. The naturally-occurring microorganisms that are obtainable by the means and methods of the present invention can be used for adsorbing toxins from pathogenic microorganisms and/or blocking receptors for such toxins on the surface of mammalian cells. These toxin-receptor interactions are known to be critical for disease pathogenesis, making both the toxins and receptors a target for the naturally-occurring microorganisms of the present invention.

Resumen de: AU2018210554A1

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Resumen de: US2019255136A1

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

Resumen de: AU2019210656A1

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD 8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin- derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. 5 The present invention provides cell-targeted, CDS+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capabl e of delivering one or more 10 heterologous T- cell epitopes to the MHC class I presentation pathway, including polypeptides which are I ) B- cell and/or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and/or 3) comprises toxin effectors which retain toxin functions.

Resumen de: WO2018069538A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

Resumen de: US2019250159A1

Disclosed herein are example embodiments of a transformative sensor apparatus that is capable of detecting and quantifying the presence of a substance of interest such as a specified bacteria within a sample via changes in impedance exhibited by a detection electrode array. In an example embodiment, sensitivity is improved by including a focusing electrode array in a rampdown channel to focus a concentration of the substance of interest into a detection region. The focusing electrodes include an opposing pair of electrodes in a rampdown orientation. The focusing electrode may also include tilted thin film finger electrodes extending from the rampdown electrodes. In another example embodiment, trapping electrodes are positioned to trap a concentration of the substance of interest onto the detection electrode array.

Resumen de: WO2019154032A1

Provided is a salmonella phage, particularly relating to a long-tail broad host spectrum salmonella pullorum strong lytic phage. Said salmonella pullorum phage is named SP4, being collected in the China General Microbiological Culture Collection Centre, the collection date being 27 July 2017, and the collection number being CGMCC No. 14332. The phage has a strong lytic effect on salmonella, and the phage can also reduce the mortality of chicks infected with pullorosis. The preparation can be used individually or in a cocktail to provide a safe, non-toxic, and non-residual action phage product source for the treatment of salmonella infections from poultry, ducks, mink, food sources, and pigs.

Resumen de: US2019247465A1

The present invention relates to an immunomodulator for the prevention or treatment of an allergic disease caused by house dust mite-derived allergens. Particularly, the present invention provides an immunomodulatory pharmaceutical composition comprising as an effective ingredient a bacteria extracellular vesicle containing an allergens derived from North American house dust mite or European house dust mite, and a preparation method therefor.

Resumen de: AU2018239310A1

The present invention relates to bacteriocins for control of

Resumen de: PH12018000039A1

The invention describes banana pseudostem-based liquid extracts and its applications as an antimicrobial against Escherichia coli, Salmonella typhimurium, and Staphylococcus aureus, and as a quorum sensing inhibition agent against Pseudomonas aeruginosa. The formulations are either in ethanolic or aqueous forms. The extracts were tested against Escherichia coli, Salmonella typhimurium, Staphylococcus aureus via disc diffusion method; and Pseudomonas aeruginosa via agar diffusion assay and the zones of inhibition were observed. Results include and antibacterial and quorum sensing inhibition activity in the extracts, especially in the autoclaved aqueous forms.

Resumen de: US2018100159A1

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.

Resumen de: EP3524265A1

The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.

Resumen de: WO2018069538A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.